...we evaluated sICs on 23 patients with advanced or metastatic HNSCC treated with chemotherapy or anti PD-1 antibody...Using the UVA, the treatment type (i.e., nivolumab, p = 0.024) and median sLAG3 > 377 pg/mL (Figure 2, p = 0.047) were significantly associated with lower PFS (Table 3)....Furthermore, patients with high sLAG3 showed a significant lower PFS (p = 0.047) and OS (p = 0.001) compared to those with low baseline value (Figure 2 and Figure 3)....Baseline sLAG > 377 pg/mL was found to be a significant prognostic factor of OS (p = 0.005), while it was associated to PFS as a trend (p = 0.067, Table 4).